Cost Burden/ Burden of Hospitalization For R/R ALL Patients

Explore expert insights from Dr. Pawan Kumar Singh, Dr. Roshan Dikshit, Dr. Manisha Jain, and Dr. Avriti Baveja on the cost and hospitalization burden for R/R ALL patients.

Speakers : Dr. Pawan Kumar Singh , Dr. Manisha Jain , Dr. Roshan Dikshit , Dr. Avriti Baveja

Expert Group meeting with the management of EGFR mutation positive NSCLC - Part I

In this webinar, a detailed discussion is done on Expert group convenes to discuss management strategies for EGFR mutation-positive NSCLC.

Speakers : Dr. Vineet Govinda Gupta ( Moderator ) ,Dr. Atul Sharma ( Panelist ) ,Dr. Abhishek Bansal ( Panelist )

Expert Group meeting with the management of EGFR mutation positive NSCLC - Part III

Expert meeting discussing management strategies and therapies for EGFR mutation-positive non-small cell lung cancer.

Speakers : Dr. Abhishek Bansal ( Panelist ) ,Dr. Atul Sharma ( Panelist ) ,Dr. Vineet Govinda Gupta ( Moderator )

Expert Group meeting with the management of EGFR mutation positive NSCLC - Part IV

Expert panel discusses targeted therapies and strategies for managing EGFR mutation-positive non-small cell lung cancer.

Speakers : Dr. Vineet Govinda Gupta ( Moderator ) ,Dr. Atul Sharma ( Panelist ) ,Dr. Abhishek Bansal ( Panelist )

Dacomitinib Case Presentation: Baseline Treatment and Current Status

Explore Dr. Viraj Nevrekar’s expert insights on Dacomitinib in NSCLC, covering baseline treatment approaches, efficacy, and real-world case studies.

Speakers : Dr Viraj Nevrekar- (Moderator)

Dissecting Molecular differences between EGFR Exon 19 deletion and Exon 21 L858R Mutations

Explore Dr. Viraj Nevrekar’s expert analysis on the molecular and clinical differences between EGFR Exon 19 deletion and Exon 21 L858R mutations in NSCLC.

Speakers : Dr. Viraj Nevrekar

First Line Combination Therapy- The Overall Survival Data in NSCLC Patients

Dr. Viraj Nevrekar discusses first-line combination therapy and overall survival data in NSCLC, covering immunotherapy, targeted therapy, and chemotherapy.

Speakers : Dr. Viraj Nevrekar

L858R Mutation- An Overview of Retrospective Cohort Study in Advanced NSCLC Patients

Explore Dr. Viraj Nevrekar’s analysis of the L858R mutation in advanced NSCLC through a retrospective cohort study, covering treatment outcomes, survival trends, and clinical outcomes

Speakers : Dr. Viraj Nevrekar

Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update) - Part V

In this webinar, a detailed discussion is done on CROWN trial update: Optimizing 1st-line ALK+ mNSCLC management.

Speakers : Dr Srujna Joga ( Expert Panel ) ,Dr AP Dubey ( Expert Panel ) ,Dr Atul Sharma ( Expert Panel ) ,Dr Jyoti Wadhwa ( Moderator )

Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update) - Part IV

In this webinar, a detailed discussion is done on CROWN trial update: Optimizing 1st-line ALK+ mNSCLC management.

Speakers : Dr Srujna Joga ( Expert Panel ) ,Dr AP Dubey ( Expert Panel ) ,Dr Atul Sharma ( Expert Panel ) ,Dr Jyoti Wadhwa ( Moderator )


Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

In leukemia, allogeneic HCT is beneficial following primary induction failure.

2.

Team finds broken 'brake' on cancer mutation machine.

3.

Omega Fatty Acid Changes Tied to Lower Proliferation Rate in Early Prostate Cancer

4.

Prostate cancer screening program beneficial in top decile of polygenic risk score

5.

Talk About Medication Costs, Bringing Back Touch, and Understanding From Dish Tumors.


© Copyright 2025 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot